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Abstract: Encapsulating a drug molecule into a water-reactive
metal–organic framework (MOF) leads to amorphous drug
confined within the nanoscale pores. Rapid release of drug
occurs upon hydrolytic decomposition of MOF in dissolution
media. Application to improve dissolution and solubility for
the hydrophobic small drug molecules curcumin, sulindac, and
triamterene is demonstrated. The drug@MOF composites
exhibit significantly enhanced dissolution and achieves high
supersaturation in simulated gastric and/or phosphate buffer
saline media. This combination strategy where MOF inhibits
crystallization of the amorphous phase and then releases drug
upon MOF irreversible structural collapse represents a novel
and generalizable approach for drug delivery of poorly soluble
compounds while overcoming the traditional weakness of
amorphous drug delivery: physical instability of the amor-
phous form.
Oral delivery is the preferred route for drug administration
due to its convenience, high patient compliance, and cost-
effectiveness. If drug dissolution is fast in the gastrointestinal
tract, relatively rapid absorption and the accompanying onset
of therapeutic activity is observed.[1] Achieving the desired
concentration to facilitate drug absorption depends on
solubility under physiological conditions, and poor aqueous
solubility is a significant challenge in drug development and
formulation. Drug candidates being generated in the R&D
pipeline, and many currently marketed drugs, suffer from
poor solubility.[2,3] A number of approaches for improving
solubility have been pursued, such as amorphous solid
dispersions using appropriate polymeric excipients,[4–6] coc-
rystallization,[7, 8] and solubilization in co-solvents.[9] Although
these approaches can improve performance relative to pure
drugs, each has various drawbacks, mainly related to the
chemical stability of the drug and physical stability against
crystallization. Thus, there still is a need for methodologies to
improve drug solubility with the ultimate goal being a general
platform for amorphous drug stabilization during storage and
administration. Here, a general approach to improve drug
solubility is demonstrated by incorporating drugs into
a metal–organic framework (MOF); the MOF acts as a drug
carrier that inhibits crystallization of drug by confinement
within its nanoscale pores and yet undergoes rapid hydrolytic
decomposition in simulated gastric (SG) and phosphate
buffer saline (PBS) media leading to immediate release of
an amorphous drug (Figure 1). This amorphous delivery
system exhibits an increase in the free energy of drug relative
to the crystalline form which is essential for generating high
supersaturation. To our knowledge, this methodology for
encapsulation and immediate release of pharmaceuticals has
not been previously reported.
Current approaches employing MOFs in drug delivery
center around controlled release.[10, 11] For example, MOFs
have been demonstrated to be excellent candidates for micro/
nanomedicine-extended or controlled cargo delivery.[12–16] In
these delivery models, MOFs with long-term chemical
stability in media serve as drug release regulators upon
activation by diverse stimuli such as media pH, temperature
or pressure.[10] MOFs using a slow drug release model are
beneficial for moderate to high solubility compounds and may
improve chemical stability[12–15] of molecules by limiting total
exposure of the compound in the digestive tract. This
approach competes with polymers used as drug delivery
vehicles for controlled release.[17–20] In contrast, here the
immediate release of an amorphous drug in aqueous media
from a drug@MOF composite via MOF hydrolytic degrada-
tion is leveraged for enhancing drug dissolution and solubil-
ity; this approach represents a general platform for delivering
poorly soluble drugs.
When considering an appropriate MOF to serve as an
amorphous drug stabilizer and fast release host the major
considerations are 1) acceptable toxicity profile, 2) reactive
decomposition in appropriate media, and 3) suitable pore size
to host drug targets. Based on these criteria, MOF-5 was
selected as the host as it is built from zinc clusters and
terephthalic acid.[21] Zinc is a used in many dietary vitamin
and mineral supplements, in which zinc exists as zinc oxide,
zinc acetate or zinc gluconate. The organic linker terephthalic
acid exhibits low toxicity and a very high safe oral dose (lethal
dose, LD50 over 1 gkg
@1 in a mouse model).[22,23] Most
importantly, MOF-5 is unstable to hydrolysis due to cleavage
of coordination bonds in humid environments.[24] The struc-
ture of MOF-5 exhibits large pores (& 12.5 c diameter)
suitable for hosting small molecule therapeutics.[22] Poorly
water-soluble drug candidates curcumin (CUR), sulindac
(SUL), and triamterene (TAT) were selected as the guest
molecules. CUR is a hydrophobic polyphenol with dimen-
sions & 17.3 X 6.9 c. CUR displays potential therapeutic
benefits such as antioxidant, anti-tumor, anti-inflammatory,
anti-malarial, anti-bacterial, anti-viral, anti-hyperglycemic
activities and acts against AlzheimerQs disease.[25, 26] CUR
suffers from poor aqueous solubility, which impairs oral
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bioavailability. SUL is a poorly soluble, non-steroidal anti-
inflammatory drug with dimensions 13.8 X 7.6 c.[27] TAT is
a potassium-sparing diuretic drug with dimensions 11.8 X
7.6 c that exhibits poor solubility.[28]
Drug molecules were encapsulated via post-synthetic
incorporation by soaking activated MOF-5 crystals in excess
of a drug in methylene chloride (for CUR) or acetonitrile (for
SUL and TAT) (see Experimental section in the Supporting
Information). The drug@MOF-5 composite crystals were
removed by filtration and washed twice with the same solvent
used for the incorporation to eliminate residual drug on the
outside surface of MOF-5. The crystals were activated under
vacuum. Optical microscopy (Figure 2a) shows the dramatic
color change upon encapsulation of drug; CUR@MOF-5 is
brick red and the SUL@MOF-5 and TAT@MOF-5 compo-
sites are yellow. Powder X-ray diffraction (PXRD) patterns of
the composites demonstrate MOF-5 phase stability as crys-
tallinity is retained after encapsulation of drug (Figure 2b and
c). No diffraction peaks associated with drug molecules are
observed, consistent with the pores being too small to support
aggregation into a crystalline form. Proton NMR spectra of
drug@MOF-5 composites, after digestion in acidic
[D6]DMSO, (see Figure S1, Supporting Information) reveal
that the drugs do not degrade upon loading.
Host–guest interactions of drug@MOF-5 composites were
analyzed using vibrational spectroscopy. Infrared (IR) and
Raman spectra of drug@MOF-5 composites show strong
similarities when compared to the crystalline starting compo-
nents although peak shifts are evident in both host and guest
(see Figures S2 and S3 and characteristic peaks listed in
Table S1 in the Supporting Information). The IR spectrum of
pure CUR exhibits a hydroxyl stretch at 3510 cm@1 which is
shifted to lower frequency in CUR@MOF-5 (3509 cm@1). The
Raman spectrum of pure CUR contains a carbonyl stretch at
1627 cm@1 which is red shifted in CUR@MOF-5 to 1626 cm@1.
This contrasts with the blue shifting in pure amorphous CUR
and is consistent with significant attractive drug–MOF
interactions in the composite.[29] Shifting also occurs in the
IR and Raman spectra of SUL when the molecule is
incorporated into MOF-5. Red shifting of the carboxylic
acid stretch at 1697 cm@1 to 1677 cm@1 in the IR spectrum and
red shifting of peaks at 1209 and 1118 cm@1 (to 1208 and
1115 cm@1 respectively) in the Raman spectrum is observed
and these results are mirrored in TAT@MOF-5. These data
are consistent with substantial
attractive drug-MOF interac-
tions in the composite which
should contribute to long-term
stability of amorphous phase
against crystallization.
Weight percentage (wt %)
of the incorporated drug in
drug@MOF-5 composite was
determined using UV-vis spec-
troscopy on digested samples
(see Supporting Information).
Drug encapsulation in MOF-5
was found to be 7.7 wt % for
CUR, 22.4 wt % for SUL, and
34.0 wt % for TAT. This demon-
strates 0.18 CUR, 0.61 SUL,
and 1.61 TAT molecules per
cage in MOF-5 were encapsu-
lated, respectively (TAT encap-
Figure 1. Schematic representation of a drug encapsulated into MOF followed by the immediate release of drug from drug@MOF composite via
MOF hydrolytic decomposition.
Figure 2. a) Optical images of MOF-5 and drug@MOF-5 composites crystals. b,c,d) PXRD patterns of
drug@MOF-5 composites compared with their starting materials (MOF-5 and respective drug).
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sulation in MOF-5 shown as an example in Figure 3). The
achieved drug loading (wt%) for drug@MOF-5 composites
are promising and comparable with drug–polymer solid
dispersions, drug-polymer micelles, and nanomedicine–poly-
mer composites where the drug loading is in range of & 5 to
50% with respect to the carrier.[30–32] Furthermore, gas
sorption analysis reveals that the BET surface area decreases
in all the composites (CUR@MOF-5 (2777 m2 g@1),
SUL@MOF-5 (1969 m2 g@1) and TAT@MOF-5 (550 m2 g@1))
relative to pure MOF-5 (3425 m2 g@1) which shows that the
pores of MOF-5 are occupied by drug molecules (see
Figure S3, Supporting Information). This residual porosity
follows the same trend as the wt % drug loading consistent
with partial pore blockage; similar results were observed for
polymer–MOF composites.[33] Residual porosity is important
for allowing fast entry of water into the MOF to promote
rapid framework degradation, although the tradeoff between
porosity and drug loading must be optimized for each drug
ultimately consistent with desired dosage and dissolution
behavior.
To investigate host decomposition behavior, MOF-5
crystals were soaked in SG and PBS media at 37 8C. The
undissolved material from these media was determined by
PXRD to be terephthalic acid in SG media, whereas a PBS
media resulted in a Zn-terephthalate-dihydrate salt precip-
itate among other decomposition products[34] (see Figure S4,
Supporting Information). The drug@MOF-5 composites
exhibit decomposition behavior akin to pure MOF-5 (see
Figure S5–S7, Supporting Information). Notably,
SUL@MOF-5 decomposition in SG media resulted in SUL
crystallized as form I (monoclinic) polymorph rather than as
the more stable form II (orthorhombic); this finding is in
accord with the Ostwald step rule.[35, 36]
To determine drug dissolution rates and supersaturation
generation from drug@MOF-5 composites, and from physical
mixtures (PM), UV-vis spectroscopy was used to monitor the
dissolution process at 37 8C (Figures 4a–d and Table 1).
Methyl cellulose was included in both dissolution media to
inhibit precipitation of drug molecules at high supersaturation
and to serve as a proxy for what would be an extensive
formulation process of this supersaturating drug delivery
system. The shape of the drug concentration vs. time curves
for CUR@MOF-5 in both media indicates that CUR under-
goes rapid dissolution and maintains high supersaturation.
Immediate release of CUR molecules from CUR@MOF-5 via
MOF hydrolytic decomposition leads to rapid dissolution
which generates high supersaturation in the first 60 min. A
maximum concentration (Cmax) of 8.5 mgmL
@1 in SG media
and 13.9 mgmL@1 in PBS media are observed and demonstrat-
ing that CUR@MOF-5 achieves a much higher CUR
concentration upon dissolution than pure CUR. This imme-
diate drug release from drug@MOF-5 composite is in contrast
with controlled drug release from an amorphous drug@MOF
composite with a water stable framework.[37] A CUR/MOF-5
PM displays a dissolution profile similar to pure CUR in both
media, indicating that encapsulation is critical for perfor-
mance. Moreover, CUR@MOF-5 achieves supersaturation
significantly greater than that generated during the dissolu-
tion of CUR polymeric amorphous solid dispersions.[38]
Sulindac is a poorly water-soluble weak acid with pH-
dependent solubility which exhibits a very low solubility in
Figure 3. Illustration of the encapsulation of TAT drug into a MOF-5
(approx. two TAT molecules per cage were encapsulated in MOF-5).
Figure 4. Representative CUR, CUR@MOF-5 and physical mixture
(PM) dissolution profiles in (a) SG and (b) PBS media. c) Representa-
tive SUL, SUL@MOF-5, and SUL/MOF-5 PM dissolution profiles in
SG media. d) Representative TAT, TAT@MOF-5 and TAT/MOF-5 PM
dissolution profiles in PBS media.
Table 1: Representative drugs, drug@MOF-5 composites and their PM
Cmax and AUC0-4 values (average (standard error of the mean)) in SG and/
or PBS media.
Compound Cmax [mg mL
@1] AUC0-4 [mghmL
@1]
SG media PBS media SG media PBS media
CUR 2.12(21) 0.95(4) 0.39(6) 0.15(2)
CUR/MOF-5PM 2.16(3) 1.03(1) 0.39(6) 0.19(3)
CUR@MOF-5 8.45(19) 13.87 (27) 1.75(2) 2.88(4)
SG media SG media
SUL 6.84(7) 1.38(2)
SUL/MOF-5 PM 14.06(6) 2.83(5)
SUL@MOF-5 50.73(41) 9.92(13)
PBS media PBS media
TAT 26.89(8) 5.89(9)
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SG media.[35] It is important to note that during dissolution of
SUL@MOF-5 and SUL/MOF-5 PM in SG media, the pH
slightly increases due to MOF-5 decomposition products. This
change in the pH leads to substantial changes in SUL
solubility. Immediate release of SUL from SUL@MOF-5
generates high supersaturation in the first 60 min of dissolu-
tion with a maximum concentration of 50.7 mg mL@1. As
dissolution continues, the concentration of SUL declines
slowly due to SUL precipitation from media. Nonetheless,
Cmax and AUC values of SUL@MOF-5 are much greater than
pure SUL. Furthermore, SUL@MOF-5 achieves superior
supersaturation as compared to SUL polymeric amorphous
solid dispersions, which exhibit a Cmax of < 33 mgmL
@1 in
SG.[39]
Triamterene is a weakly basic drug that exhibits low
solubility in neutral solutions and intestinal pH. Immediate
release of TAT from TAT@MOF-5 generates high super-
saturation in the first 20 min of dissolution with a maximum
concentration of up to 55.5 mg mL@1 which demonstrates that
TAT@MOF-5 achieves enhanced concentration upon disso-
lution than pure TAT. A TAT/MOF-5 PM displays a dissolu-
tion profile similar to pure TAT.
Amorphous form stability is a critical problem in drug
delivery, and we hypothesized that confinement in pores
would block pharmaceutical crystallization indefinitely.
Indeed, all the composites have good physical stability of
more than 4 months in dry conditions at room temperature
(see Figure S9, Supporting Information).
In conclusion, a new approach is demonstrated for
enhancing the solubility of poorly soluble drugs using
a water reactive MOF as a drug carrier. Encapsulating drug
in MOF-5 to form a drug@MOF composite inhibits crystal-
lization of amorphous phase drug (stable > 4 months) and
facilitates immediate drug release in dissolution media upon
hydrolytic MOF decomposition. The studied composites
show fast drug release to generate high supersaturation,
which offers the potential for enhanced drug absorption and
rapid onset of therapeutic activity. The present supersaturat-
ing drug delivery system for immediate drug release formu-
lations can be broadly applied to pharmaceutically acceptable
water reactive MOFs and a large number of poorly soluble
drug molecules as host–guest systems for enhancing drug
solubility in a general fashion.
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